NYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $233.47 +11.66 (+5.26%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$224.27▼$233.9250-Day Range$199.66▼$233.4752-Week Range$161.65▼$275.00Volume646,107 shsAverage Volume534,594 shsMarket Capitalization$12.03 billionP/E Ratio27.47Dividend YieldN/APrice Target$252.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Charles River Laboratories International alerts: Email Address Charles River Laboratories International MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside8.1% Upside$252.29 Price TargetShort InterestHealthy3.53% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment1.06Based on 8 Articles This WeekInsider TradingSelling Shares$295,969 Sold Last QuarterProj. Earnings Growth12.37%From $10.99 to $12.35 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.51 out of 5 starsMedical Sector105th out of 936 stocksCommercial Physical Research Industry5th out of 12 stocks 2.3 Analyst's Opinion Consensus RatingCharles River Laboratories International has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageCharles River Laboratories International has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Charles River Laboratories International's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.53% of the outstanding shares of Charles River Laboratories International have been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently increased by 1.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCharles River Laboratories International has received a 76.18% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Charles River Laboratories International is -0.55. Previous Next 3.4 News and Social Media Coverage News SentimentCharles River Laboratories International has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Charles River Laboratories International this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for CRL on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows5 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $295,969.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 12.37% in the coming year, from $10.99 to $12.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is 27.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is 27.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 155.18.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 2.13. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Charles River Laboratories International's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About Charles River Laboratories International Stock (NYSE:CRL)Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Read More CRL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRL Stock News HeadlinesJuly 25 at 3:23 AM | americanbankingnews.comCharles River Laboratories International, Inc. (NYSE:CRL) Receives $252.29 Consensus Target Price from BrokeragesJuly 24 at 10:07 AM | finance.yahoo.comCharles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug DiscoveryJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 16, 2024 | globenewswire.comCRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary DutiesJuly 5, 2024 | benzinga.comCharles River Could be an Apt Pick Right Now: Here's WhyJune 25, 2024 | businesswire.comCharles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical CampusJune 17, 2024 | businesswire.comCharles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell TherapyJune 12, 2024 | globenewswire.comCRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary DutiesJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 6, 2024 | globenewswire.comCRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary DutiesMay 31, 2024 | seekingalpha.comCharles River Laboratories: Fair Valuation Against FundamentalsMay 30, 2024 | businesswire.comCharles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy DevelopmentMay 28, 2024 | businesswire.comTitian Receives Multi-Year Commitment from Charles River for Mosaic Sample Management SoftwareMay 14, 2024 | gurufocus.comInsider Sale: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL)May 13, 2024 | markets.businessinsider.comCharles Rhyee Maintains Hold on Charles River Labs Amidst Revenue and Market UncertaintiesMay 9, 2024 | markets.businessinsider.comCharles River Laboratories Reaffirms FY24 Outlook; Q1 Results Top EstimatesMay 9, 2024 | msn.comCharles River Laboratories Non-GAAP EPS of $2.27 beats by $0.21, revenue of $1.01B beats by $16.54MMay 9, 2024 | finance.yahoo.comCharles River Laboratories Announces First-Quarter 2024 ResultsSee More Headlines Receive CRL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Commercial physical research Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CUSIP15986410 CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees21,800Year Founded1947Price Target and Rating Average Stock Price Target$252.29 High Stock Price Target$290.00 Low Stock Price Target$205.00 Potential Upside/Downside+8.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$8.50 Trailing P/E Ratio27.47 Forward P/E Ratio21.24 P/E Growth2.13Net Income$474.62 million Net Margins10.81% Pretax Margin13.36% Return on Equity15.16% Return on Assets6.60% Debt Debt-to-Equity Ratio0.73 Current Ratio1.75 Quick Ratio1.37 Sales & Book Value Annual Sales$4.13 billion Price / Sales2.91 Cash Flow$17.65 per share Price / Cash Flow13.23 Book Value$70.15 per share Price / Book3.33Miscellaneous Outstanding Shares51,510,000Free Float50,840,000Market Cap$12.03 billion OptionableOptionable Beta1.38 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. James C. Foster J.D. (Age 73)CEO, President & Chairman Comp: $2.66MMs. Flavia H. Pease (Age 51)Corporate Executive VP & CFO Comp: $1.66MMs. Birgit Girshick (Age 54)Corporate Executive VP & COO Comp: $1.28MMr. Joseph W. LaPlume (Age 50)Corporate Executive Vice President of Corporate Development & Strategy Comp: $928.36kMr. William D. Barbo (Age 63)Corporate Executive Vice President of Community Relations Comp: $1MMr. Michael Gunnar Knell (Age 47)Corporate Senior VP & Chief Accounting Officer Prof. Julie Frearson Ph.D.Corporate Senior VP & Chief Scientific OfficerMr. Mark MintzCorporate Senior VP & Chief Information OfficerTodd SpencerCorporate Vice President of Investor RelationsMr. Matthew L. DanielCorporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance OfficerMore ExecutivesKey CompetitorsAgilent TechnologiesNYSE:AMettler-Toledo InternationalNYSE:MTDIlluminaNASDAQ:ILMNWatersNYSE:WATBio-TechneNASDAQ:TECHView All CompetitorsInsiders & InstitutionsAmica Mutual Insurance Co.Bought 6,313 shares on 7/26/2024Ownership: 0.043%EFG Asset Management North America Corp.Bought 1,571 shares on 7/26/2024Ownership: 0.033%State of Michigan Retirement SystemBought 100 shares on 7/26/2024Ownership: 0.027%Atomi Financial Group Inc.Sold 82 shares on 7/26/2024Ownership: 0.004%Patriot Financial Group Insurance Agency LLCBought 379 shares on 7/26/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $236.40 on January 1st, 2024. Since then, CRL stock has decreased by 1.2% and is now trading at $233.47. View the best growth stocks for 2024 here. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) announced its earnings results on Thursday, May, 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.05 by $0.22. The medical research company earned $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a trailing twelve-month return on equity of 15.16%. Read the conference call transcript. What is James C. Foster's approval rating as Charles River Laboratories International's CEO? 291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees. Does Charles River Laboratories International have any subsidiaries? The following companies are subsidiaries of Charles River Laboratories International: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and more. Who are Charles River Laboratories International's major shareholders? Charles River Laboratories International's top institutional investors include Allspring Global Investments Holdings LLC (2.43%), Bank of New York Mellon Corp (0.93%), Raymond James & Associates (0.48%) and Boston Trust Walden Corp (0.39%). Insiders that own company stock include James C Foster, Birgit Girshick, Joseph W Laplume, William D Barbo, Victoria L Creamer, Michael Gunnar Knell, George Massaro, Shannon M Parisotto, Richard F Wallman, Deborah Turner Kochevar and David Ross Smith. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM) and Abbott Laboratories (ABT). This page (NYSE:CRL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles River Laboratories International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
